Search fresh public links, source activity, and ready-to-use post angles for Allogene Therapeutics.
Fresh curated links around Allogene Therapeutics are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
An allogeneic CAR T-cell therapy company is planning a pivotal Phase III randomized-control trial, hoping their products can reach more patients and help those who can’t access aut...
AlloPort today announced its planned public launch on September 1, 2026, followed by its industry debut at the AATB Annual Conference in San Francisco on October 4.
The Delhi company designs and manufactures its own cell and gene therapies and is preparing a first clinical trial with Christian Medical College, Vellore.
The Gurugram-based company is developing allogeneic CAR-NK cell therapies made from healthy donor cells, backed by a $4.2 million seed round and a government grant covering both re...
Created for the tissue banking industry by tissue banking veterans AlloPort combines veteran healthcare leadership, Cisco-pioneered data aggregation technology, and a simple 10% tr...
Researchers generated off-the-shelf, mass-producible iPSC-derived allogeneic γδT cells that in a small preclinical study suppressed tumor growth in mouse colorectal cancer xenograf...
Lonza, through one of its affiliated companies, is eligible to receive upfront, clinical, regulatory, and commercial milestone payments, plus royalties on the net sales of resultin...
A new analysis of patients who took part in clinical trials for Kite Pharma’s CAR-T cell therapy Yescarta has revealed genetic signatures of toxicity risk, potentially providing a...
Tolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein in certain thymus-related indications in the Americas a...
The only TIL therapy approved so far is Amtagvi for melanoma. Here are six companies with promising TIL therapies in the clinic. The post Six TIL therapy companies to watch out for...
Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.
New NK cell platform extends RMTG's cellular-technology portfolio into immunology-adjacent applications, with an initial commercial focus on Latin America and Southeast Asia.
Among the first projects identified under the partnership is a Phase 2 extension study evaluating the safety and efficacy of IMN-003A cell therapy in adult and paediatric patients...
Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discu...
The HiBiT Target Cell Killing (TCK) platform, with off-the-shelf, mix-and-match components, measures four killing mechanisms for broad immunotherapy modality assessment. The post A...
Roche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the growing pool of patients who progress after treatment with...
Cellares plans to translate the manufacturing of SonomaBio’s SBT-77-7101 onto its Cell Shuttle and automate in-process and release testing through the Cell Q quality control syste...
Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and...
For years, cell therapy has carried one of oncology’s most striking contradictions. It has changed the outlook for some blood cancer patients, yet has struggled to make the same im...
The collaboration brings together Synastra’s expertise in genomic engineering, AAV vector design, rare-disease gene therapy, and translational development with NewBiologix’s propri...
By modulating Notch and T cell receptor signaling, scientists have produced functional CD4+ T cells from iPSCs, potentially advancing scalable, off-the-shelf CAR T therapies. The p...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.